arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

GT Biopharma, Inc.

GTBP
$4.51 ▼ -0.30 (-6.24%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
28 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, GT Biopharma, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $175.1M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -99.9% ↘
FCF / Share $-0.11 ↘
Trailing P/E —
Price / Book 56.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-4.52M
↓ -215.3% —
Operating Margin Operating profit as % of sales
-416.0%
↓ -443.8% —
FCF / Share Free cash flow per share
$-0.11
↓ -34.6% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -327.1% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.46x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 65 quarters